Jonathan Sheena Sells 2,700 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.87, for a total transaction of $293,949.00. Following the completion of the transaction, the insider now owns 301,808 shares in the company, valued at $32,857,836.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Tuesday, June 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $109.66, for a total transaction of $296,082.00.
• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $108.30, for a total transaction of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $89.55, for a total transaction of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The shares were sold at an average price of $92.47, for a total transaction of $2,468,949.00.

Natera Stock Up 0.8 %

Shares of NTRA stock opened at $111.64 on Friday. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $117.23. The firm has a 50-day moving average price of $106.10 and a 200 day moving average price of $87.05. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The firm had revenue of $367.70 million during the quarter, compared to the consensus estimate of $316.31 million. During the same period last year, the firm posted ($1.23) EPS. The firm’s quarterly revenue was up 52.1% on a year-over-year basis. On average, research analysts predict that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Piper Sandler raised their price target on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 14th. TD Cowen raised their price target on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Canaccord Genuity Group raised their price target on shares of Natera from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. The Goldman Sachs Group raised their price target on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Finally, Craig Hallum assumed coverage on shares of Natera in a research report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.19.

Hedge Funds Weigh In On Natera

Several institutional investors have recently added to or reduced their stakes in NTRA. Envestnet Asset Management Inc. lifted its holdings in Natera by 68.3% during the 3rd quarter. Envestnet Asset Management Inc. now owns 178,350 shares of the medical research company’s stock valued at $7,892,000 after purchasing an additional 72,400 shares during the last quarter. Northern Trust Corp increased its position in Natera by 0.8% in the 3rd quarter. Northern Trust Corp now owns 533,889 shares of the medical research company’s stock valued at $23,625,000 after acquiring an additional 4,291 shares in the last quarter. Natixis Advisors L.P. acquired a new stake in Natera in the 3rd quarter valued at about $666,000. Treasurer of the State of North Carolina increased its position in Natera by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock valued at $2,012,000 after acquiring an additional 230 shares in the last quarter. Finally, Kynam Capital Management LP increased its position in Natera by 3.6% in the 3rd quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock valued at $132,912,000 after acquiring an additional 103,668 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.